Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Inflammation × Pregabalin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1 Breast 1

Conditions

Pain 3 Neuralgia 3 Breast Neoplasms 3 Seizures 1 Pinealoma 1 Oligodendroglioma 1 Obesity 1 Neuroectodermal Tumors, Primitive 1 Neoplasms 1 Myotoxicity 1 Meningioma 1 Medulloblastoma 1 Lymphoma 1 Inflammation 1 Head and Neck Neoplasms 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Ependymoma 1 Earache 1 Drug-Related Side Effects and Adverse Reactions 1 Central Nervous System Neoplasms 1 Brain Neoplasms 1 Astrocytoma 1 Agnosia 1

Interventions

XENP 1595 2 salicylsalicylic acid 1 microcrystalline cellulose 1 ginger extract 1 epigallocatechin gallate 1 dapagliflozin 1 Tablets 1 Sulindac 1 Specimen Handling 1 Sodium Salicylate 1 Radiotherapy, Conformal 1 Pregabalin 1 Omeprazole 1 Losartan 1 Ketorolac 1 Interleukin 1 Receptor Antagonist Protein 1 Infliximab 1 Etanercept 1 Atorvastatin 1 Ascorbic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06150898 2025-06-13

KePreSt

Jules Bordet Institute

Phase 2 Recruiting

Breast Neoplasms, Inflammation, Obesity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡